Rheumatoid Arthritis

Factors independently associated with persistently active RA included age, gender, previous or current smoking status, and social deprivation.

A new study shows RA is linked to an increased risk of hematological tumors and bladder, lung, and liver cancer compared to the general population.

Results from a Mendelian randomization analysis indicate type 1 diabetes significantly increases the likelihood of autoimmune conditions like rheumatoid arthritis and multiple sclerosis.

Jacques-Eric Gottenberg, MD, PhD, discusses the encouraging results of a phase 2 study evaluating nipocalimab for the treatment of Sjögren's syndrome.

The rheumatology month in review for June 2024 addresses the critical role of psychological, socioeconomic, and lifestyle factors in the management of rheumatic diseases, particularly rheumatoid arthritis and fibromyalgia.

Diana Girnita, MD, PhD, highlights the crucial role of patient education, the integration of traditional and integrative medicine, and the importance of reliable information for improving health outcomes in chronic conditions.

A study presented at EULAR 2024 found anxiety, depression, and sleep disorders were significantly correlated to pain intensity.

Patients with RA and obesity exhibited worse scores for subjective measures like pain and fatigue compared to those without obesity.

RA was linked to an increased risk of ischemic and hemorrhagic strokes, with further analysis revealing sex-based differences in stroke outcomes in men vs women with RA.

A study presented at EULAR 2024 found patients with RA of low socioeconomic status have a high prevalence of fatigue.

Compared to patients on stable TNFi, patients tapering TNFi to withdrawal experienced significantly more flares and had lower Boolean 2.0 remission rates.

A study presented at EULAR 2024 found fibromyalgia and worse pain, symptom severity, and depression scores were linked to a risk of low medication adherence.

More than half of patients with RA or PsA without obesity exhibited steatosis despite having low disease activity, with no differences observed based on methotrexate use and dosage.

Positive personality traits and perceived disease impact may play a larger role in explaining sleep disturbances in patients with RA than disease activity, anxiety, or depression.

Patients with RA had a greater risk of delayed cervical cancer screening, and smoking was associated with a decrease in prostate cancer screening in patients with RA.

Presented at EULAR 2024, a study suggested controlling RA disease activity may be important from a psycho-social perspective.

Findings from a 2-year extension of the Plants for Joints randomized controlled trial show promise for the long-term benefits of diet, physical activity, and stress management in RA.

Findings underscore the impact of socioeconomic factors on disease management and therapeutic outcomes in patients with rheumatoid arthritis from different socioeconomic classes.

Among all groups, fewer men with rheumatic disease were childless compared with controls.

Findings showed the rates of TEAEs were generally similar between upadacitinib 15 mg and active comparators in RA and PsA.

CD40L blockade with dazodalibep benefited disease activity scores, including tender and swollen joints, in patients with moderate-to-severe active RA.

Treatment with romosozumab or denosumab demonstrated comparable results among patients with either primary osteoporosis or those with rheumatoid arthritis complicated with osteoporosis over a 24-month period.

A national survey provides insight into the prevalence of arthritis based on race in the US from 2011 – 2018.

Patients who achieved early remission with upadacitinib or adalimumab following an inadequate response to methotrexate had less pain/fatigue and better physical quality of life.

Patients with the highest daily step count had a 45% lower risk of RA compared with patients in the lowest quarter (< 6818 daily steps).

The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.

A study presented at EULAR 2024 found tender joint count was linked to depression and illness perception but not anxiety.

Phase 2 data showed a significant reduction in RA disease activity at Week 12 with weekly abiprubart, compared with placebo.

Phase 3 data showed patients treated with SHR0302 4 mg or 8 mg had greater improvements in ACR20 response rates and other key secondary outcomes versus placebo.

Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.